MICHAEL AMENTA: Open Payments
NPI 1225511223 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$255 in 13 payments from 6 companies in 2025. Trend: 2023 $271 · 2024 $150 · 2025 $255
Food & beverage: $255
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $58 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Alkermes, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| ABBVIE INC. | 1 | $18 |
Products named: INVEGA SUSTENNA, COBENFY, ABILIFY MAINTENA, UZEDY, VRAYLAR, ARISTADA, LYBALVI, VIVITROL.
Industry payments across NE — which companies pay providers there.
